activated protein c resistance

Summary

Summary: A hemostatic disorder characterized by a poor anticoagulant response to activated protein C (APC). The activated form of Factor V (Factor Va) is more slowly degraded by activated protein C. Factor V Leiden mutation (R506Q) is the most common cause of APC resistance.

Top Publications

  1. ncbi Effect of hemostatic risk factors on the individual probability of thrombosis during pregnancy and the puerperium
    Andrea Gerhardt
    Department of Hemostasis and Transfusion Medicine, Heinrich Heine University Medical Center, Dusseldorf, Germany
    Thromb Haemost 90:77-85. 2003
  2. ncbi Learning from peer assessment: the role of the external quality assurance multilaboratory thrombophilia test process
    Emmanuel J Favaloro
    Haemostasis Laboratories, Department of Haematology, Institute of Clinical Pathology and Medical Research ICPMR, Westmead Hospital, Westmead, New South Wales, Australia
    Semin Thromb Hemost 31:85-9. 2005
  3. ncbi High frequency of thrombophilic disorders in women with recurrent fetal miscarriage
    L Onderoglu
    Department of Obstetrics and Gynecology, Hacettepe University School of Medicine, Ankara, Turkey
    Clin Exp Obstet Gynecol 33:50-4. 2006
  4. ncbi Mechanisms for acquired activated protein C resistance in cancer patients
    G Sarig
    J Thromb Haemost 3:589-90. 2005
  5. ncbi Superficial vein thrombosis, thrombin generation and activated protein C resistance as predictors of thromboembolic events in lupus and antiphospholipid patients. A prospective cohort study
    Stéphane Zuily
    CHU de Nancy, Vascular Medicine Division and Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases, Nancy, F 54000, France
    Thromb Res 132:e1-7. 2013
  6. ncbi Activated protein C resistance and lupus anticoagulant activity induced by plasma and purified monospecific human IgG anti-beta2-glycoprotein-I antibodies
    Martha E Viveros
    Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
    Rev Invest Clin 57:563-71. 2005
  7. ncbi Acquired activated protein C resistance associated with IgG antibodies against beta2-glycoprotein I and prothrombin as a strong risk factor for venous thromboembolism
    Junzo Nojima
    Laboratory for Clinical Investigation, Osaka University Hospital, Osaka, Japan
    Clin Chem 51:545-52. 2005
  8. ncbi Increased acquired activated protein C resistance in unselected patients with hematological malignancies
    H F S Negaard
    Department of Hematology, Ulleval University Hospital Trust, Oslo, Norway
    J Thromb Haemost 6:1482-7. 2008
  9. ncbi Activated protein C resistance (FV(Leiden)) and thrombosis: factor V mutations causing hypercoagulable states
    Gerry A F Nicolaes
    Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Post Office Box 616, 6200 MD, Maastricht, The Netherlands
    Hematol Oncol Clin North Am 17:37-61, vi. 2003
  10. ncbi The cytoprotective protein C pathway
    Laurent O Mosnier
    Department of Molecular and Experimental Medicine MEM 180, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA, USA
    Blood 109:3161-72. 2007

Detail Information

Publications212 found, 100 shown here

  1. ncbi Effect of hemostatic risk factors on the individual probability of thrombosis during pregnancy and the puerperium
    Andrea Gerhardt
    Department of Hemostasis and Transfusion Medicine, Heinrich Heine University Medical Center, Dusseldorf, Germany
    Thromb Haemost 90:77-85. 2003
    ..The high prevalence of combined and homozygous defects of hemostatic components (21.6%) in patients as compared with normal women (0.86%) supports the concept that venous thromboembolism is a multicausal disorder...
  2. ncbi Learning from peer assessment: the role of the external quality assurance multilaboratory thrombophilia test process
    Emmanuel J Favaloro
    Haemostasis Laboratories, Department of Haematology, Institute of Clinical Pathology and Medical Research ICPMR, Westmead Hospital, Westmead, New South Wales, Australia
    Semin Thromb Hemost 31:85-9. 2005
    ..for the common markers of congenital thrombophilia, such as antithrombin, protein C, protein S, and activated protein C resistance. Testing of some acquired markers of thrombophilia, such as lupus anticoagulant, and genetic tests ..
  3. ncbi High frequency of thrombophilic disorders in women with recurrent fetal miscarriage
    L Onderoglu
    Department of Obstetrics and Gynecology, Hacettepe University School of Medicine, Ankara, Turkey
    Clin Exp Obstet Gynecol 33:50-4. 2006
    ..Our purpose was to examine whether genetic thrombophilias are etiological factors for recurrent fetal miscarriage or not...
  4. ncbi Mechanisms for acquired activated protein C resistance in cancer patients
    G Sarig
    J Thromb Haemost 3:589-90. 2005
  5. ncbi Superficial vein thrombosis, thrombin generation and activated protein C resistance as predictors of thromboembolic events in lupus and antiphospholipid patients. A prospective cohort study
    Stéphane Zuily
    CHU de Nancy, Vascular Medicine Division and Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases, Nancy, F 54000, France
    Thromb Res 132:e1-7. 2013
    ..Our objective was to determine risk factors for thrombotic events including activated protein C (APC) resistance proven by a thrombin generation (TG) assay in patients with SLE and/or aPL...
  6. ncbi Activated protein C resistance and lupus anticoagulant activity induced by plasma and purified monospecific human IgG anti-beta2-glycoprotein-I antibodies
    Martha E Viveros
    Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
    Rev Invest Clin 57:563-71. 2005
    We investigated the activated protein C resistance (APCR) phenotype and the lupus anticoagulant (LA), activity induced by anti-beta2-glycoprotein-I (anti-beta2GP-I) antibodies.
  7. ncbi Acquired activated protein C resistance associated with IgG antibodies against beta2-glycoprotein I and prothrombin as a strong risk factor for venous thromboembolism
    Junzo Nojima
    Laboratory for Clinical Investigation, Osaka University Hospital, Osaka, Japan
    Clin Chem 51:545-52. 2005
    ..Our aim was to clarify the roles of anti-phospholipid (aPL) antibodies in the pathogenesis of venous thromboembolism (VTE) in patients with systemic lupus erythematosus (SLE)...
  8. ncbi Increased acquired activated protein C resistance in unselected patients with hematological malignancies
    H F S Negaard
    Department of Hematology, Ulleval University Hospital Trust, Oslo, Norway
    J Thromb Haemost 6:1482-7. 2008
    ..Acquired activated protein C (APC) resistance may be another mechanism responsible for such hypercoagulation, and has been demonstrated in patients with solid tumors, but not in patients with hematological malignancy...
  9. ncbi Activated protein C resistance (FV(Leiden)) and thrombosis: factor V mutations causing hypercoagulable states
    Gerry A F Nicolaes
    Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Post Office Box 616, 6200 MD, Maastricht, The Netherlands
    Hematol Oncol Clin North Am 17:37-61, vi. 2003
    ..In this article, the authors focus on the protein C anticoagulant pathway and the role of activated protein C resistance in thrombotic disease, and they discuss the involvement in thrombosis of mutations other than the ..
  10. ncbi The cytoprotective protein C pathway
    Laurent O Mosnier
    Department of Molecular and Experimental Medicine MEM 180, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA, USA
    Blood 109:3161-72. 2007
    ....
  11. ncbi Factor V Leiden and acquired activated protein C resistance among 1000 women with recurrent miscarriage
    R Rai
    Department of Reproductive Science and Medicine, Imperial College School of Medicine at St Mary s, London, UK
    Hum Reprod 16:961-5. 2001
    ..0%:12/300; 12 heterozygotes). Acquired but not congenital APC resistance (due to the factor V Leiden mutation) is associated with both early and late miscarriage...
  12. ncbi Activated protein C resistance (APCR) and placental fibrin deposition
    S Sedano
    National Diagnostics Centre, National University of Ireland, Galway, Ireland
    Placenta 29:833-7. 2008
    b>Activated protein C resistance (APCR) results in an ineffective anticoagulant response leading to an increased risk of thrombosis, particularly during pregnancy...
  13. ncbi Factor V Leiden and post thromboembolic pulmonary hypertension
    Albinas Naudziunas
    Clinic of Internal Medicine, Kaunas University of Medicine, A Mickeviciaus 9, 3000 Kaunas, Lithuania
    Medicina (Kaunas) 39:1171-4. 2003
    Literature review and original data concerning the most common cause of inherited thrombophilia - activated protein C resistance have been presented...
  14. ncbi Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women
    Guido Tans
    Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands
    Br J Haematol 122:465-70. 2003
    ..In addition, acquired APC resistance resulting from OC use predicts an increased risk for venous thrombosis independent of factor V Leiden...
  15. ncbi Factor V mutations in Iranian patients with activated protein C resistance and venous thrombosis
    Rouzbeh Chegeni
    Department of Hematology and Blood Banking, School of Medicine, Tarbiat Modarres University, Jalale ale Ahmad Ave, Tehran, Iran
    Thromb Res 119:189-93. 2007
  16. ncbi High prevalence of activated protein C resistance and factor V Leiden mutation in an Arab population and patients with venous thrombosis in Kuwait
    Mehrez M Jadaon
    Department of Medical Laboratory Sciences, Kuwait University, Kuwait
    Diagn Mol Pathol 19:180-3. 2010
    b>Activated protein C resistance (APC-R) because of clotting factor V Leiden mutation (FVL; Arg506Gln; G1691A) is a risk factor for the development of venous thromboembolic disorders (VTE)...
  17. ncbi Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: a multicenter collaborative family study
    P Bucciarelli
    Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital and University of Milan, Italy
    Arterioscler Thromb Vasc Biol 19:1026-33. 1999
    Deficiencies of antithrombin (AT), protein C (PC) or protein S (PS), and activated protein C resistance (APCR) are very well-established coagulation defects predisposing to venous thromboembolism (VTE)...
  18. ncbi [Activated protein C resistance and deep venous thrombosis in pregnancy]
    M Prochazka
    Porodnicko gynekologická klinika FN a LF UP Olomouc
    Ceska Gynekol 67:251-4. 2002
    ..The aim of the study was to detect the incidence of resistance to activated protein C in pregnant or puerperal women with confirmed diagnosis of deep venous thrombosis or pulmonary embolism...
  19. ncbi [Prevalence of the activated protein C resistance in indigenous and Black populations of the western Venezuela]
    G Vizcaino
    Instituto de Investigaciones Clinicas, Facultad de Medicina, Universidad del Zulia, Maracaibo, Venezuela
    Invest Clin 41:29-36. 2000
    The Activated Protein C Resistance (APCR) is the common phenotype of Factor V Leiden (arg506gln), which is considered as a thrombotic risk factor...
  20. pmc Antiphospholipid antibodies and thrombosis: association with acquired activated protein C resistance in venous thrombosis and with hyperhomocysteinemia in arterial thrombosis
    Jeannine Kassis
    Department of Hematology, Hopital Maisonneuve Rosemont, Universite de Montreal, Montreal, Quebec, Canada
    Thromb Haemost 92:1312-9. 2004
    ..between factor V Leiden and venous thrombosis, hyperhomocysteinemia and arterial thrombosis, and activated protein C resistance (APCR) and venous thrombosis (OR, 95% CI = 4.00, 1.35-11.91; 4.79, 2.03-11.33; and 2.03, 1.03-3...
  21. ncbi Haemostatic changes and acquired activated protein C resistance in normal pregnancy
    Boris Mahieu
    Laboratory of Haemostasis and Haematology, Antwerp University Hospital, Edegem, Belgium
    Blood Coagul Fibrinolysis 18:685-8. 2007
    ..The clinical significance of this finding should be determined because it complicates the interpretation of lowered APC-SR...
  22. ncbi Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications
    M Zangari
    Central Arkansas Veteran s Healthcare System, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
    Blood Coagul Fibrinolysis 13:187-92. 2002
    ..In conclusion, in this series, acquired APC resistance was present in almost one-quarter of newly diagnosed myeloma patients and significantly increased the risk of DVT...
  23. ncbi The discovery of activated protein C resistance
    B Dahlback
    Department of Laboratory Medicine, Division of Clinical Chemistry, Lund University, The Wallenberg Laboratory, Malmo, Sweden
    J Thromb Haemost 1:3-9. 2003
    ..I have been asked to write a personal historical annotation about the discovery of APC resistance, the early research activities and the rapid progress in this field...
  24. ncbi [National evaluation of the diagnosis of activated protein C resistance]
    Guadalupe Montiel-Manzano
    Laboratorio de Coagulación Especial, Hospital de Especialidades, CMN SXXI, IMSS, Mexico, D F
    Rev Invest Clin 55:358-69. 2003
    ..Since searching of activated protein C resistance (APCR) and FV Leiden seem to have priority either in the clinical setting and in public health ..
  25. ncbi Activated protein C resistance and factor V Leiden: a review
    Adam Rosendorff
    Department of Pathology, Brigham and Women s Hospital, Boston, Mass 02115, USA
    Arch Pathol Lab Med 131:866-71. 2007
    ..Carriers of FVL have an increased susceptibility to venous thrombosis, which is further increased in the presence of other genetic or environmental risk factors...
  26. ncbi Functional properties of factor V and factor Va encoded by the R2-gene
    L Hoekema
    Department of Biochemistry, Cardiovascular Research Institute, Maastricht, Maastricht University, The Netherlands
    Thromb Haemost 85:75-81. 2001
    ....
  27. ncbi Genetic polymorphisms on the factor V gene in women with recurrent miscarriage and acquired APCR
    Feroza Dawood
    Department of Reproductive and Developmental Health, Liverpool Women s Hospital, University of Liverpool, Crown Street, Liverpool L8 7SS, UK
    Hum Reprod 22:2546-53. 2007
    Recurrent miscarriage (RM) has been associated with the thrombophilia, activated protein C resistance (APCR)...
  28. ncbi Activated protein C resistance in Turkish women with severe preeclampsia
    M Cetin
    Department of Internal Medicine, Division of Hematology, Erciyes University Medical School, Kayseri, Turkey
    Gynecol Obstet Invest 52:168-72. 2001
    ..05). Our results indicate that acquired APC-R may be a contributory factor in the pathogenesis of preeclampsia...
  29. ncbi The factor VIII D1241E polymorphism is associated with decreased factor VIII activity and not with activated protein C resistance levels
    Daniela Scanavini
    Department of Biochemistry and Molecular Biology, Ferrara University, Italy
    Thromb Haemost 93:453-6. 2005
    ..Our findings point toward the presence of genetic determinant of coagulation factor levels with a biologically significant role, but with a poor predictive value to estimate thrombotic risk beyond established risk factors...
  30. ncbi A new locus on chromosome 18 that influences normal variation in activated protein C resistance phenotype and factor VIII activity and its relation to thrombosis susceptibility
    Jose Manuel Soria
    Unitat d Hemostasia i Trombosi, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
    Blood 101:163-7. 2003
    b>Activated protein C resistance (APCR) is the most prevalent risk factor for thrombosis, accounting for 20% to 60% of familial thrombophilia...
  31. ncbi Activated protein C resistance in preeclampsia
    S Cagirgan
    Division of Hematology, Department of Internal Medicine, Ege University Faculty of Medicine, Izmir, Turkey
    Clin Exp Obstet Gynecol 31:59-62. 2004
    ..In this study the incidence of activated protein C resistance (APCR) in preeclamptic women was evaluated.
  32. ncbi Factor V Leiden: association with venous thromboembolism in pregnancy and screening issues
    D Harvey
    Department of Haematology, Arrowe Park Hospital, Arrowe Park Road, Upton, Wirral CH49 5PE
    Br J Biomed Sci 61:157-64. 2004
    ..Pregnant women with a history of VTE or with a family history of the mutation are investigated. Whether or not the introduction of a routine screening plan for this mutation is justified remains a matter for debate...
  33. ncbi Activated protein C resistance in anterior ischaemic optic neuropathy
    Valeria Nagy
    Department of Ophthalmology, Medical and Health Science Centre, University of Debrecen, Debrecen, Hungary
    Acta Ophthalmol Scand 82:140-3. 2004
    ..The aim of this retrospective study was to determine the prevalence of APC resistance and Leiden mutation in patients with non-arteritic anterior ischaemic optic neuropathy (NAION)...
  34. ncbi Activated protein C resistance (FV:Q506) and pregnancy
    P G Lindqvist
    Department of Obstetrics and Gynecology, Lund University, University Hospital, Malmo, Sweden
    Thromb Haemost 81:532-7. 1999
    ..361 ml) (p = 0.04). Despite the high prevalence of APC resistance in this series of gravidae (11%), its presence was unrelated to adverse pregnancy outcome apart from an 8-fold increased risk of VTE...
  35. ncbi Response to activated protein C decreases throughout pregnancy
    Chiara Benedetto
    Department of Gynecology and Obstetrics, University Hospital, University of Turin, Italy
    Acta Obstet Gynecol Scand 81:1028-32. 2002
    ..The possibility that changes in activated protein C anticoagulant activity may contribute to the hemostatic changes associated with pregnancy has been previously investigated, but the results of the studies are still controversial...
  36. ncbi Activated protein C resistance -- in the absence of factor V Leiden -- and pregnancy
    P G Lindqvist
    Department of Clinical Science, Malmo University Hospital, Lund University, Malmo, Sweden
    J Thromb Haemost 4:361-6. 2006
    ..Many previous pregnancy studies have been focused on APC resistance caused by FVL. Very few have investigated APC resistance in the absence of FVL (APCR(FVL-))...
  37. ncbi Spontaneous thrombosis in mice carrying the factor V Leiden mutation
    J Cui
    Division of Medical Genetics, Department of Human Genetics, University of Michigan Medical Center, Ann Arbor MI, USA
    Blood 96:4222-6. 2000
    ..Blood. 2000;96:4222-4226)..
  38. ncbi Frequency of polymorphisms in the B-domain of factor V gene in APC-resistant patients
    H Kostka
    Institute of Clinical Chemistry und Laboratory Medicine, Dresden, Germany
    Thromb Res 99:539-47. 2000
    ..We suggest that the G allele, which is not associated with the FV Leiden mutation, as well as the [2379G; 2540C; 4070G] allele have no influence on the APC cofactor function itself, or only subtly as determined in the test systems used...
  39. ncbi Double heterozygosity for Factor V Leiden and Factor V Cambridge mutations associated with low levels of activated protein C resistance in a Spanish thrombophilic family
    Amparo Santamaria
    Hemostasis and Thrombosis Unit, Department of Hematology, Hospital de la Santa Creu i Sant Pau, C Sant Antoni Ma Claret, 167, 08025 Barcelona, Spain
    Thromb Haemost 93:1193-5. 2005
  40. ncbi The HR2 haplotype of factor V: effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis
    M C de Visser
    Dept of Hematology, Leiden University Medical Center, The Netherlands
    Thromb Haemost 83:577-82. 2000
    ..However, the HR2 haplotype is associated with a reduced sensitivity for APC in carriers of FVL and with reduced factor V antigen levels...
  41. ncbi Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis
    Gianluca Gessoni
    Clinical Pathology Laboratory, Ospedale Civile, Chioggia, Venice, Italy
    Blood Coagul Fibrinolysis 18:603-10. 2007
    ..In the authors' experience this prothrombin time-based method was not influenced by many factors compared with the classical activated partial thromboplastin time-based method...
  42. ncbi Prothrombin gene mutation G20210A, homocysteine, antiphospholipid antibodies and other hypercoagulable states in ocular thrombosis
    Elizabeth M Van Cott
    Division of Laboratory Medicine, Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Blood Coagul Fibrinolysis 15:393-7. 2004
    ..patients with ocular thromboses (vein, artery, or choriocapillaris occlusions) underwent testing for activated protein C resistance/factor V Leiden, prothrombin G20210A, lupus anticoagulant, anticardiolipin antibodies, ..
  43. ncbi The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus
    Jan Leendert P Brouwer
    Division of Haemostasis, Thrombosis and Rheology, Department of Hematology, University Hospital Groningen The Netherlands
    Blood 104:143-8. 2004
    ..In conclusion, factor V Leiden and the prothrombin mutation contribute to the risk of VTE in patients with SLE, and potentiate this risk when one of these thrombophilic defects are combined with LA and/or ACAs...
  44. ncbi The contribution of factor V Leiden and prothrombin G20210A mutation to the risk of central venous catheter-related thrombosis
    Cornelis J van Rooden
    Department of General Internal Medicine Leiden University Medical Center LUMC, Leiden, The Netherlands
    Haematologica 89:201-6. 2004
    ....
  45. ncbi Spinal dural arteriovenous fistulas are not associated with prothrombotic factors
    K Jellema
    Department of Neurology, St Elisabeth Hospital Tilburg, The Netherlands
    Stroke 35:2069-71. 2004
    ..In intracranial dural arteriovenous fistulas, an association with factor V Leiden mutation has been found. Therefore, we studied the association between prothrombotic factors and SDAVF...
  46. ncbi Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study
    E R Pomp
    Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands
    J Thromb Haemost 6:632-7. 2008
    ..Venous thrombosis is one of the leading causes of maternal morbidity and mortality...
  47. ncbi Relationship between thrombophilic disorders and type of severe early-onset hypertensive disorder of pregnancy
    Wessel Ganzevoort
    Department of Obstetrics and Gynaecology, Academic Medical Centre, Amsterdam, The Netherlands
    Hypertens Pregnancy 26:433-45. 2007
    ....
  48. ncbi Factor V Leiden--the commonest molecular defect in arterial and venous thrombophilia in India
    Rafeeq P H Ahmed
    Department of Haematology, All India Institute of Medical Sciences, IRCH Building 1st Floor, Ansari Nagar, New Delhi 110 029, India
    Thromb Res 110:19-21. 2003
  49. ncbi Inherited risk factors for venous thromboembolism: implications for clinical practice
    Paul M Ridker
    Cardiovascular Division, Division of Preventive Medicine, Brigham and Women s Hospital, USA
    Clin Cornerstone 4:18-30. 2002
    ..Thus, identification of high-risk patients with genetic predispositions to thrombosis is an important clinical goal, particularly among individuals with recurrent DVT...
  50. ncbi Evaluation of the Roche LightCycler: a simple and rapid method for direct detection of factor V Leiden and prothrombin G20210A genotypes from blood samples without the need for DNA extraction
    Peter C Cooper
    Sheffield Haemophilia and Thrombosis Centre, Royal Hallamshire Hospital, UK
    Blood Coagul Fibrinolysis 14:499-503. 2003
    ..Similarly, the prothrombin G20210A mutation showed complete agreement for wild-type (n = 135), heterozygous (n = 63) and homozygous (n = 2) subjects...
  51. ncbi [Thrombophilia risk factors evaluation in a group of Italian patients with deep venous thrombosis]
    Sara Valverde
    Servizio di Medicina di Laboratorio, Ospedale, Chioggia
    Recenti Prog Med 99:348-53. 2008
    ..Venous thrombosis usually results from coexistence of multiple genetic and acquired risk factors with a trigger condition. In this study the authors report their experience in a cohort of Italian patients with previous venous thrombosis...
  52. ncbi The epidemiology of venous thromboembolism in Caucasians and African-Americans: the GATE Study
    N F Dowling
    Haematologic Diseases Branch, Division of AIDS, STD, and TB Laboratory Research, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA
    J Thromb Haemost 1:80-7. 2003
    ..Our findings underscore the need to determine gene polymorphisms associated with VTE in African-Americans...
  53. ncbi [Exercise deep venous thrombosis: myth or reality? About three cases of pulmonary embolism in long-distance runners]
    B Fremont
    Service de cardiologie A USCI, Hopital Trousseau, Centre Hospitalier Universitaire de Tours, 37044 Tours Cedex
    Arch Mal Coeur Vaiss 100:519-23. 2007
    ..To our knowledge, very few similar cases have ever been reported. The possible responsibility of such physical efforts is discussed, as well as other potential cofactors such as coagulation abnormalities and hormonal contraception...
  54. ncbi Effect of age on oral contraceptive-induced venous thrombosis
    A Girolami
    University of Padua Medical School, Department of Medical and Surgical Science, Second Chair of Medicine, Padua, Italy
    Clin Appl Thromb Hemost 10:259-63. 2004
    ..Because the majority of women took preparations that contained third-generation progestins during the second course of therapy, concomitant contributing effects of these compounds cannot be excluded...
  55. ncbi Factor V Leiden: a disorder of factor V anticoagulant function
    Elisabetta Castoldi
    Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, 6200 MD Maastricht, The Netherlands
    Curr Opin Hematol 11:176-81. 2004
    ..The present review covers the discovery, the physiological significance and the structural requirements of the APC-cofactor activity of FV...
  56. ncbi Evaluation of thrombotic children with malignancy
    Selma Unal
    Section of Pediatric Hematology, Department of Pediatrics, Faculty of Medicine, Hacettepe University, 06100, Ankara, Turkey
    Ann Hematol 84:395-9. 2005
    ....
  57. ncbi An overview of methods for detection of factor V Leiden and the prothrombin G20210A mutations
    P C Cooper
    Department of Coagulation, Sheffield Haemophilia and Thrombosis Centre, Royal Hallamshire Hospital, Sheffield, UK
    Int J Lab Hematol 29:153-62. 2007
    ..This article is aimed at reviewing the available methods for the detection of factor V Leiden and prothrombin G20210A mutations, their principle, applicability, advantages and disadvantages of use...
  58. ncbi Thrombophilia and venous thromboembolism. International consensus statement. Guidelines according to scientific evidence
    A N Nicolaides
    Int Angiol 24:1-26. 2005
    ..The aim of this document is to provide guidelines for investigation and management of patients with thrombophilia in the presence or absence of venous thromboembolism (VTE)...
  59. ncbi An underestimated combination of opposites resulting in enhanced thrombotic tendency
    Paolo Simioni
    Department of Medical and Surgical Sciences, Second Chair of Internal Medicine, University of Padua Medical School, Padua, Italy
    Blood 106:2363-5. 2005
    ..venous thromboembolism, but the thrombosis risk associated with this rare condition (pseudohomozygous activated protein C resistance) is still unclear...
  60. ncbi Recurrent thrombotic occlusion of a transjugular intrahepatic portosystemic stent-shunt due to activated protein C resistance
    Elmar Siewert
    Department of Internal Medicine III, Aachen University, Aachen, Germany
    World J Gastroenterol 11:5064-7. 2005
    ..If risk factors are confirmed, anticoagulation should be intensified. There are currently no evidence-based recommendations regarding the best available anticoagulant therapy and surveillance protocol for patients with TIPS...
  61. ncbi APC-PCI complex concentration is higher in patients with previous venous thromboembolism with Factor V Leiden
    K Strandberg
    J Thromb Haemost 3:2578-80. 2005
  62. ncbi The risk of recurrent venous thromboembolism in patients with inherited deficiency of natural anticoagulants antithrombin, protein C and protein S
    Valerio De Stefano
    Institute of Hematology, Catholic University, Rome, Italy
    Haematologica 91:695-8. 2006
    ..9, 95% CI 1.0-3.9); the carriers of PC or PS deficiency had a marginal increase in risk (hazard ratio 1.4, 95% CI 0.9-2.2). In conclusion, patients with AT deficiency are potential candidates for long-term oral anticoagulation...
  63. ncbi Multilaboratory testing in thrombophilia through the United Kingdom National External Quality Assessment Scheme (Blood Coagulation) Quality Assurance Program
    Ian Jennings
    United Kingdom NEQAS Blood Coagulation, Sheffield, United Kingdom
    Semin Thromb Hemost 31:66-72. 2005
    ..Studies in the NEQAS laboratory confirmed the effect of activated protein C resistance (APCR) on clot-based PC activity assays...
  64. ncbi Multilaboratory testing of thrombophilia: current and past practice in Australasia as assessed through the Royal College of Pathologists of Australasia Quality Assurance Program for Hematology
    Emmanuel J Favaloro
    Haematology Laboratories, Institute of Clinical Pathology and Medical Research ICPMR, Westmead Hospital, New South Wales, Australia
    Semin Thromb Hemost 31:49-58. 2005
    ..thrombophilia, tests evaluated comprised protein C (PC), protein S (PS), antithrombin (AT), and activated protein C resistance (APCR)...
  65. ncbi Intraindividual consistency of the activated protein C resistance phenotype
    Alberto Tosetto
    Hemophilia and Thrombosis Centre, Department of Haematology, S Bortolo Hospital, Vicenza, Italy
    Br J Haematol 126:405-9. 2004
    ..4%) were carriers of the G20210A prothrombin allele. APC resistance not due to FV Leiden is a frequent and consistent phenotype in the general population, with a possibly strong genetic influence...
  66. ncbi Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities
    Ida Martinelli
    Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Internal Medicine and Dermatology, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Maggiore Policlinico, University of Milano, Italy
    Circulation 110:566-70. 2004
    ..Risk factors for primary upper-extremity DVT are not well established, and the recurrence rate is unknown...
  67. ncbi Primary upper-extremity deep vein thrombosis: high prevalence of thrombophilic defects
    Mariela F Hendler
    Departamento de Hemostasia y Trombosis, Instituto de Investigaciones Hematologicas Mariano R Castex, Academia Nacional de Medicina de Buenos Aires, Buenos Aires, Argentina
    Am J Hematol 76:330-7. 2004
    ..Hypercoagulable status may play a significant role in both groups. Screening for local anatomical abnormalities and thrombophilia should be included in the evaluation of primary UEDVT...
  68. ncbi Prevalence of factor V Leiden mutation and other hereditary thrombophilic factors in Egyptian children with portal vein thrombosis: results of a single-center case-control study
    Hanaa El-Karaksy
    Department of Pediatrics, Faculty of Medicine, Cairo University, Cairo, Egypt
    Ann Hematol 83:712-5. 2004
    ..Protein C, protein S, antithrombin III, and activated protein C resistance (APCR) were assayed. Molecular study of factor II and factor V mutations was carried out...
  69. ncbi The response to activated protein C after cardiopulmonary bypass: impact of factor V leiden
    Brian S Donahue
    Department of Anesthesiology, 504 Oxford House, Vanderbilt University, Nashville, TN 37232, USA
    Anesth Analg 99:1598-603, table of contents. 2004
    ..These findings provide mechanistic support for previous speculations of increased postoperative thrombotic risk associated with FVL...
  70. ncbi Effects of random allocation to vitamin E supplementation on the occurrence of venous thromboembolism: report from the Women's Health Study
    Robert J Glynn
    Division of Preventive Medicine, Brigham and Women s Hospital, 900 Commonwealth Ave E, Boston, MA 02215 1204, USA
    Circulation 116:1497-503. 2007
    ..Supplementation with vitamin E may antagonize vitamin K in healthy adults, but it is unclear whether intake of vitamin E decreases the risk of venous thromboembolism (VTE)...
  71. ncbi The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies
    Antonio Marchiori
    Department of Emergency Medicine, St Anthony Hospital, University of Padua, Padua, Italy
    Haematologica 92:1107-14. 2007
    ..The risk is lower with PTM and is difficult to interpret since it varies according to the assessment method used...
  72. ncbi A review of the clinical and diagnostic utility of laboratory tests for the detection of congenital thrombophilia
    Armando Tripodi
    Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Internal Medicine, University and IRCCS Maggiore Hospital, Milan, Italy
    Semin Thromb Hemost 31:25-32. 2005
    ....
  73. ncbi [Thromboembolic diseases. XVIIIth Congress of the International Society on Thrombosis and Haemostasis, Paris, 6-12 July 2001]
    M Lambert
    Service de Medecine Interne, Hopital Claude Huriez, CHU, 59037 Lille, France
    Rev Med Interne 23:238-42. 2002
  74. ncbi Primary thrombophilia in Mexico. II. Factor V G1691A (Leiden), prothrombin G20210A, and methylenetetrahydrofolate reductase C677T polymorphism in thrombophilic Mexican mestizos
    G J Ruiz-Arguelles
    Centro de Hematologia y Medicina Interna de puebla, Mexico
    Am J Hematol 66:28-31. 2001
    ..We have shown that in Mexican mestizo patients with clinical features of primary thrombophilia, 39% have activated protein C resistance phenotype, 5% protein C deficiency, and 2% protein S deficiency...
  75. ncbi Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia
    I Martinelli
    Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital, University of Milan, Italy
    Thromb Haemost 86:800-3. 2001
    ..On the basis of these findings we recommend that these women receive anticoagulant prophylaxis at least in the postpartum, that should perhaps be extended to the whole pregnancy in homozygous carriers...
  76. ncbi The plasminogen activator inhibitor (PAI)-1 promoter 4G/4G genotype is not associated with ischemic stroke in a population of German children. Childhood Stroke Study Group
    U Nowak-Gottl
    Paediatric Haematology and Oncology, University Hospital Munster, Germany
    Eur J Haematol 66:57-62. 2001
    ..To investigate the relationship between an insertion/deletion (4G/5G) polymorphism of the plasminogen activator inhibitor (PAI)-1 gene and childhood patients with a past history of ischemic stroke...
  77. ncbi Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium
    Ida Martinelli
    Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital, University of Milan, Italy
    Thromb Haemost 87:791-5. 2002
    ..Among thrombophilic abnormalities, the prothrombin mutation was the weakest risk factor. Thrombosis occurred more frequently in puerperium than in pregnancy, whether or not thrombophilia was diagnosed...
  78. ncbi Thrombosis: new culprits in an old disorder
    D G Federman
    VA Connecticut Health Care System and Department of Medicine, Yale University School of Medicine, New Haven, CT, USA
    Panminerva Med 44:107-13. 2002
    ..Newly described abnormalities associated with thrombophilia include the syndrome of activated Protein C resistance (APCR), the prothrombin 20210A mutation, hyperhomocysteinemia, and elevated levels of coagulation ..
  79. ncbi Ala147Thr and C+1542G polymorphisms in the TAFI gene are not asssociated with a higher risk of venous thrombosis in FV Leiden carriers
    P E Morange
    Thromb Haemost 86:1583-4. 2001
  80. ncbi Factor V Leiden (G1691A) and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery
    K Wahlander
    Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska University Hospital, Goteborg, Sweden
    Thromb Haemost 87:580-5. 2002
    ..03 and p = 0.05, respectively). However, since 90% of the patients with these genetic risk factors will not suffer a VTE event, a general pre-operative genotyping is, in our opinion, of questionable value...
  81. ncbi Foetal growth restriction in children with prothrombotic risk factors
    R von Kries
    Institute for Social Paediatrics and Adolescent Medicine, Ludwig-Maximilians-University Munich, Germany
    Thromb Haemost 86:1012-6. 2001
    ..53 (0.76-3.08) in carriers of one prothrombotic risk factor and 4.01 (1.48-10.84) in subjects carrying multiple or homozygous defects. We identified foetal thrombophilia as an additional cause of low birth weight...
  82. ncbi The use of coagulation activation markers (soluble fibrin polymer, TpP, prothrombin fragment 1.2, thrombin-antithrombin, and D-dimer) in the assessment of hypercoagulability in patients with inherited and acquired prothrombotic disorders
    Y S Arkel
    Maternal and Fetal Medicine Division, Department of Ob Gyn, NYU Medical Center, New York, New York 10016, USA
    Blood Coagul Fibrinolysis 13:199-205. 2002
    ..Our data suggest that there is a utility in performing a panel of coagulation activation markers to assess the thrombotic risk. The measurement of soluble fibrin polymer may be more reflective of an impending vascular event...
  83. ncbi D-dimer as a risk factor for deep vein thrombosis: the Leiden Thrombophilia Study
    Astrid C M Andreescu
    Department of Medicine, University of Vermont, Burlington, USA
    Thromb Haemost 87:47-51. 2002
    ..Persistence of this association in the absence of other hemostatic risk factors for DVT suggests that high D-dimer may be related to other, as yet unknown, risk factors for venous thrombosis. Confirmation of these findings is desirable...
  84. ncbi Hereditary thrombophilia in elite athletes
    Thomas Hilberg
    Department of Sports Medicine, Friedrich Schiller University Jena, Jena, Germany
    Med Sci Sports Exerc 34:218-21. 2002
    ..Because high-performance sports are known to carry an increased risk of thrombogenesis, measures to avoid thrombosis must be initiated in cases of known hereditary thrombophilia...
  85. ncbi Laboratory evaluation of hypercoagulable states in patients with central retinal vein occlusion who are less than 56 years of age
    J Michael Lahey
    Retina Unit, Department of Ophthalmology, Kaiser Permanente Medical Center, 27400 Hesperian Boulevard, Hayward, CA 94545 4299, USA
    Ophthalmology 109:126-31. 2002
    ..To investigate whether hypercoagulability plays a role in thrombus formation in patients with central retinal vein occlusion (CRVO) who are less than 56 years of age...
  86. ncbi Mutations C677T and A1298C of the 5,10-methylenetetrahydrofolate reductase gene and fasting plasma homocysteine levels are not associated with the increased risk of venous thromboembolic disease
    T B Domagala
    Department of Medicine, Jagellonian University School of Medicine, Krakow, Poland
    Blood Coagul Fibrinolysis 13:423-31. 2002
    ..In conclusion, the polymorphisms C677T and A1298C of MTHFR and fasting plasma homocysteine levels do not seem to be significant risk factors for venous thromboembolic disease...
  87. ncbi Complexes between activated protein C and protein C inhibitor measured with a new method: comparison of performance with other markers of hypercoagulability in the diagnosis of deep vein thrombosis
    K Strandberg
    Department of Clinical Chemistry, University Hospital, , Lund University, Sweden
    Thromb Haemost 86:1400-8. 2001
    ..The APC-PCI method appears to be particularly useful as a marker for detection of recently developed proximal thrombi...
  88. ncbi Acquired activated protein C resistance is associated with the co-existence of anti-prothrombin antibodies and lupus anticoagulant activity in patients with systemic lupus erythematosus
    Junzo Nojima
    Laboratory for Clinical Investigation, Osaka University Hospital, 2 15 Yamadaoka, Suita, Osaka 565 0871, Japan
    Br J Haematol 118:577-83. 2002
    ..Abs) to beta2-glycoprotein I (beta2-GP I) and prothrombin, lupus anticoagulant (LA) activity, activated protein C resistance (APC-R), and factor V Leiden in 96 patients with systemic lupus erythematosus (SLE); 19 with VTE and ..
  89. ncbi Combined carrier status of prothrombin 20210A and factor XIII-A Leu34 alleles as a strong risk factor for myocardial infarction: evidence of a gene-gene interaction
    Christopher Butt
    Discipline of Laboratory Medicine, Memorial University of Newfoundland, St John s, NF, Canada
    Blood 101:3037-41. 2003
    ....
  90. ncbi Primary thrombophilia in Mexico III: A prospective study of the sticky platelet syndrome
    Guillermo J Ruiz-Arguelles
    Centro de Hematologia y Medicina Interna de puebla, Mexico
    Clin Appl Thromb Hemost 8:273-7. 2002
    ..In addition, the activated protein C resistance phenotype, coagulation protein C activity and antigen, coagulation protein S, antithrombin III, ..
  91. ncbi Factor V and thrombotic disease: description of a janus-faced protein
    Gerry A F Nicolaes
    Department of Laboratory Medicine, Division of Clinical Chemistry, Lund University, The Wallenberg Laboratory, University Hospital Malmo, Malmo, Sweden
    Arterioscler Thromb Vasc Biol 22:530-8. 2002
    ..This review gives a description of the dualistic character of FV and describes the gene-gene and gene-environment interactions that are important for the involvement of FV in the etiology of venous thromboembolism...
  92. ncbi Hemostasis during normal pregnancy and puerperium
    Margareta Hellgren
    Department of Obstetrics and Gynecology, Göteborg University and Sahlgrenska University Hospital, Sweden
    Semin Thromb Hemost 29:125-30. 2003
    ..Increased endogenous thrombin generation, acquired activated protein C resistance, slightly decreased activated partial thromboplastin time (aPTT) and increased prothrombin complex ..
  93. ncbi The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus
    Donna Dizon-Townson
    National Institute of Child Health and Human Development Maternal Fetal Medicine Units Network, Bethesda, Maryland, USA
    Obstet Gynecol 106:517-24. 2005
    ....
  94. ncbi Comparative study of response to treatment with supraphysiologic doses of B-vitamins in hyperhomocysteinemic hemodialysis patients
    Farid Nakhoul
    Department of Nephrology, Rambam Medical Center, Haifa, Israel
    Isr Med Assoc J 6:213-7. 2004
    ..Hyperhomocysteinemia is a well-recognized risk factor for accelerated atherosclerosis in hemodialysis patients...
  95. ncbi Ethnic differences in markers of thrombophilia: implications for the investigation of ischemic stroke in multiethnic populations: the South London Ethnicity and Stroke Study
    Paula Jerrard-Dunne
    Department of Clinical Neurosciences, St George s Hospital Medical School, Cranmer Terrace, Tooting, London SW17 0RE, UK
    Stroke 34:1821-6. 2003
    ..This study estimated ethnic-specific reference ranges in a community population to determine the prevalence of thrombophilic states in a multiethnic stroke population...
  96. ncbi Protein Z levels and central retinal vein or artery occlusion
    Maya Koren-Michowitz
    Department of Hematology, Assaf Harofeh Medical Center, Zeriffin, Israel
    Eur J Haematol 75:401-5. 2005
    ..Protein Z deficiency was recently linked to increased risk of arterial thrombosis. We investigated whether CRVO and CRAO are associated with low protein Z levels...
  97. ncbi The clinical spectrum of acute renal infarction
    Ze ev Korzets
    Department of Nephrology, Meir Hospital, Kfar Saba, Israel
    Isr Med Assoc J 4:781-4. 2002
    ..Acute renal infarction is an oft-missed diagnosis. As a result, its true incidence, although presumed to be low, is actually unknown. Surprisingly, the medical literature on the subject, other than anecdotal case reports, is scarce...
  98. ncbi Thrombophilic risk factors in the pathogenesis of non-arteritic anterior ischemic optic neuropathy patients
    Taxiarchis Felekis
    University Eye Clinic of Ioannina, Kosti Palama 1, Anatoli, Ioannina, 45500, Greece
    Graefes Arch Clin Exp Ophthalmol 248:877-84. 2010
    ..Thrombophilia is the tendency/predisposition to vascular thromboses of arteries and veins, and the existence of thrombophilic risk factors leads to blood hypercoagulability and potentially increased risk for thromboses...
  99. ncbi Practical applications of snake venom toxins in haemostasis
    Neville Marsh
    The University of Adelaide, SA 5005, Australia
    Toxicon 45:1171-81. 2005
    ..Protein C and activated protein C resistance can be measured by means of RVV and Protac, a fast acting inhibitor from Southern copperhead snake ..
  100. ncbi Study of the homocysteine status in children with chronic renal failure
    Farida A Farid
    Department of Pediatrics, Faculty of Medicine, Ain Shams University, Cairo, Egypt
    Am J Nephrol 24:289-95. 2004
    ....
  101. ncbi Effect of thrombophylaxis on uterine and fetal circulation in pregnant women with a history of pregnancy complications
    J Bar
    Perinatal Division, Department of Obstetrics and Gynecology, Rabin Medical Center, Beilinson Campus, Peta Tiqva, Israel
    Thromb Res 101:235-41. 2001
    ....

Research Grants14

  1. Association of Thrombophilia and Inflammation with Post-Thrombotic Syndrome
    Mary Cushman; Fiscal Year: 2008
    ..Resultant disability is estimated at 2 million lost workdays/year and medical costs as $300 million yearly. Findings here can form the basis for development of new therapies to treat, and moreover prevent,PTS. ..
  2. SECONDARY PREVENTION TRIAL OF VENOUS THROMBOSIS-DCC
    Robert Glynn; Fiscal Year: 2002
    ..Events will be assessed by yearly visits and bi-monthly questionnaires at the time of the INR monitoring. ..
  3. Medication Use, Cormobidity and Outcomes in Aging Populations
    Robert J Glynn; Fiscal Year: 2010
    ..These studies are intended to advance methodologic strategies for evaluation of drug use and its effects in older people and to lay the foundation for interventions to improve prescribing in this population. ..
  4. STRUCTURAL STUDIES ON FIBRINOGEN AND FIBRIN
    Russell Doolittle; Fiscal Year: 2003
    ..Combined with the full structures of the native molecules at high resolution, these results should dispel much of the mystery of fibrin formation. ..
  5. Characterization of the flexible portions of fibrinogen
    Russell Doolittle; Fiscal Year: 2007
    ..These studies are aimed at determining the degree of specificity involved in the assembly of fibrin units and protofibrils as well as the relative locations of the regions involved. ..
  6. Epidemiologic Study of Placental Abruption
    Cande Ananth; Fiscal Year: 2006
    ..anticardiolipin antibodies, as well as other heritable thrombophilias including protein C deficiency, activated protein C resistance, factors VIII and XI coagulation abnormalities...
  7. Medication Use, Comorbidity and Outcomes in Aging populations
    Robert Glynn; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  8. Functional Domains of Coagulation Factor V
    Michael Kalafatis; Fiscal Year: 2007
    ..We have established a system to study phospholipids-driven macromolecular complex formation, which may be a model for the generation of complexes that form extra-and intra-cellularly. ..
  9. PDE3 Inhibitors: Selective Blockers of Oocyte Maturation
    Jeffrey Jensen; Fiscal Year: 2007
    ..This approach is expected to provide a foundation for future Phase 1 trials of PDE3 inhibitors in humans. ..
  10. Role of Coagulation System Variability: Cardiac Surgery
    Brian Donahue; Fiscal Year: 2006
    ..The project will make extensive use of data in the Vanderbilt Cardiac Surgery Registry, a valuable database of genetic and clinical data presently being prospectively collected on elective adult cardiac surgery patients...
  11. Novel targets and agents to treat thrombotic disorders
    John Griffin; Fiscal Year: 2004
    ..abstract_text> ..
  12. Platelet Activating Factor & cervical ripening
    George Saade; Fiscal Year: 2003
    ..These studies would lead to a better understanding of the mechanisms responsible for cervical ripening and therefore might improve our ability to control cervical ripening clinically. ..
  13. Determinants of Venous Thromboembolism in Older People
    Robert J Glynn; Fiscal Year: 2010
    ..Results will help identify high-risk older people, and potentially modifiable behaviors that influence risk of ..
  14. Epidemiology of Venous Thromboembolism
    Robert Glynn; Fiscal Year: 2004
    ..The results of this work may lead to new strategies for VTE preventio. ..